Article
Clinical experience of treatment of immunocompromised individuals with persistent SARS-CoV-2 infection based on drug resistance mutations determined by genomic analysis: a descriptive study.
BMC infectious diseases - 9 Nov 2023
Shimazu Haruka, Wada Daiki, Maruyama Shuhei, Inoue Akira, Kashihara Masami, Yoshihara Tomoyuki, Saito Fukuki, Yoshiya Kazuhisa, Nakamori Yasushi, Kuwagata Yasuyuki
Abstract excerpt
BACKGROUND: The efficacy of antiviral drugs that neutralize antibody drugs and fight against SARS-COV-2 is reported to be attenuated by genetic mutations of the virus in vitro. When B-cell immunocompromised patients are infected with SARS-COV-2, the infection can be prolonged, and genetic mutations can occur during the course of treatment. Therefore, for refractory patients with persistent COVID-19 infection,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.